Objective. Antiphospholipid antibodies (aPL), especially against phosphatidylserine and cardiolipin, are associated with a variety of neurological disorders. While it is believed aPL react with endothelial cells to cause cerebral thrombosis, it is not known to what degree aPL react with neural tissue nor which particular aPL specificities may be more relevant. We investigated direct aPL reactivity with the central nervous system (CNS) using 3 monoclonal IgM aPL that differentiate between cardiolipin and phosphatidylserine dependent antigens. Methods. Brain and spinal cord from normal cat Felis domesticus and brain from CD-1 mice were reacted with aPL using indirect immunoperoxidase techniques. Monoclonal aPL were reacted with whole brain my...
To study whether monoclonal anticardiolipin antibodies (aCL), derived from patients with antiphospho...
Antiphospholipid antibodies (aPL) have been associated with a variety of neurological disorders, mos...
Sera from 20 patients with antiphospholipid syndrome (APS), primary or secondary to systemic lupus e...
Objective. Antiphospholipid antibodies (aPL), especially against phosphatidylserine and cardiolipin,...
Antiphospholipid antibodies (aPL), in the presence or absence of systemic lupus erythematosus, are a...
Antibodies against phospholipids and phospholipid binding proteins (aPL) have been identified as the...
Antiphospholipid antibodies (aPL) have been associated with various neurological manifestations, but...
The reactivity of monoclonal and polyclonal antibodies directed against human central nervous system...
Although antiphospholipid syndrome (APS) is a multisystem prothrombotic condition, its inflammatory ...
Cerebrovascular disease is the most frequent clinical manifestation of the antiphospholipid syndrome...
During the past decade, the antiphospholipid antibody (aPL) syndrome has been delineated as a distin...
Antiphospholipid antibodies (aPL) have been most strongly associated with a syndrome (APS) character...
The antiphospholipid antibody syndrome (APS) is characterized by thrombocytopenia, recurrent thrombo...
Antiphospholipid antibodies (aPL) are both diagnostic and pathogenic antibodies. aPL may: (1) interf...
One of the major clinical concerns of the antiphospholipid syndrome (APS) is the propensity of antip...
To study whether monoclonal anticardiolipin antibodies (aCL), derived from patients with antiphospho...
Antiphospholipid antibodies (aPL) have been associated with a variety of neurological disorders, mos...
Sera from 20 patients with antiphospholipid syndrome (APS), primary or secondary to systemic lupus e...
Objective. Antiphospholipid antibodies (aPL), especially against phosphatidylserine and cardiolipin,...
Antiphospholipid antibodies (aPL), in the presence or absence of systemic lupus erythematosus, are a...
Antibodies against phospholipids and phospholipid binding proteins (aPL) have been identified as the...
Antiphospholipid antibodies (aPL) have been associated with various neurological manifestations, but...
The reactivity of monoclonal and polyclonal antibodies directed against human central nervous system...
Although antiphospholipid syndrome (APS) is a multisystem prothrombotic condition, its inflammatory ...
Cerebrovascular disease is the most frequent clinical manifestation of the antiphospholipid syndrome...
During the past decade, the antiphospholipid antibody (aPL) syndrome has been delineated as a distin...
Antiphospholipid antibodies (aPL) have been most strongly associated with a syndrome (APS) character...
The antiphospholipid antibody syndrome (APS) is characterized by thrombocytopenia, recurrent thrombo...
Antiphospholipid antibodies (aPL) are both diagnostic and pathogenic antibodies. aPL may: (1) interf...
One of the major clinical concerns of the antiphospholipid syndrome (APS) is the propensity of antip...
To study whether monoclonal anticardiolipin antibodies (aCL), derived from patients with antiphospho...
Antiphospholipid antibodies (aPL) have been associated with a variety of neurological disorders, mos...
Sera from 20 patients with antiphospholipid syndrome (APS), primary or secondary to systemic lupus e...